Your session is about to expire
← Back to Search
JV-GL1 for Ocular Hypertension
Study Summary
This trial will test if a new drug can safely lower eye pressure in people with glaucoma.
- Ocular Hypertension
- Open-Angle Glaucoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What medical conditions have JV-GL1 been demonstrated to improve?
"JV-GL1 is a common glaucoma medication used to treat open angle glaucoma (OAG). Additionally, JV-GL1 can be beneficial in addressing increased intra ocular pressure (IOP), inadequate reaction to other treatments, and chronic angle closure glaucoma with preceeding peripheral iridotomy or laser iridoplasty."
Is this trial actively seeking participants at present?
"The listing on clinicaltrials.gov indicates that recruitment for this particular medical trial has been closed since March 28th 2022, and it first appeared on the website in mid-March 2021. Though inactive, there are 951 other active trials currently recruiting subjects."
Is there precedent for this experiment, or is it a pioneering venture?
"At the present time, 11 ongoing trials are assessing JV-GL1 in 17 cities and 7 countries. This therapeutic was initially trialled back in 2013 by Synphora AB, with Phase 2 drug approval being reached after 100 patients were enrolled. Since then a further 138 studies have been completed."
What is the aggregate number of individuals engaging in this clinical experiment?
"At the moment, this trial is not looking for additional candidates. According to its posting date from March 10th 2021 and last edit on March 28th 2022, it has been concluded. However, there are still 940 studies seeking patients with glaucoma symptoms as well as 11 trials that require individuals suffering from JV-GL1 specifically."
Who else is applying?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger